September 2026
AliveDx, the global in vitro diagnostics company that aims to transform patient care, has received Medical Device Licence clearance from Health Canada for its MosaiQ AiPlex® CD multiplex microarray assay.
The MosaiQ® solution supports laboratories to increase testing capacity, simplify operations and support diagnosis of autoimmune diseases
Celiac disease is a chronic digestive and immune disorder, found in genetically predisposed individuals, triggered by gluten ingestion, affecting the small intestine with an estimated prevalence of about 1%.1-3 The diagnosis is often challenging due to a wide range of overlapping symptoms.
Designed for use on the MosaiQ® instrument, MosaiQ AiPlex® CD combines four markers in a single multiplex microarray, incorporating two antibody isotypes, IgA and IgG, against tissue transglutaminase (tTG) and deamidated gliadin peptides (DGP). By combining multiple markers and both isotypes, the assay is designed to enhance overall panel performance while optimizing laboratory workflow efficiency.
The assay also includes a Total IgA flag to identify potential IgA deficiency, which is reported to be up to 15 times more frequent in the coeliac population. This feature can help reduce the risk of false-negative results in patients with IgA deficiency.
Expanding the MosaiQ portfolio in Canada
This clearance follows the recent Health Canada Medical Device Licences for the MosaiQ® instrument and MosaiQ AiPlex® VAS and CTDplus Assays for Autoimmune Vasculitis and Autoimmune Connective Tissues Diseases.
MosaiQ® supports a syndromic approach to autoimmune disease diagnostics. This helps laboratories identify complex disease patterns, recognise potential comorbidities and support confident clinical decision-making. In addition, by consolidating multiple tests into one automated workflow, the microarray is designed to allow simultaneous analysis of multiple markers, help laboratories streamline testing, reduce hands-on time and increase testing capacity while providing actionable insights for clinicians.
This strengthens the availability of the MosaiQ autoimmune testing portfolio for laboratories in Canada to deliver diagnostic solutions that can generate clinical and economic value for laboratories and contribute to improved patient care.
“I am proud of the entire team for achieving the latest Health Canada Clearence to equip laboratories with comprehensive assays to support diagnosis of autoimmune diseases for patients.” said Manuel Ó. Méndez, CEO of AliveDx. “At AliveDx, we continue to address the growing needs of clinical laboratories with our product development roadmap to enable improved patient care”
Learn more about MosaiQ AiPlex® CD
1 Al-Toma A et al. United European Gastroenterol J. 2019;7(5):583-613.
2 Rubio-Tapia A et al. Am J Gastroenterol. 2023;118(1):59-76.
3 Husby S et al. J Pediatr Gastroenterol Nutr. 2020;70(1):141-156.





